Capstone Holding Corp. lowers convertible note conversion price to $1.00
John Fesko, President and Chief Business Officer of Natera, Inc. (NASDAQ:NTRA), sold shares of the company’s common stock valued at approximately $116,099. The transactions took place on March 17, 2025, and involved the sale of 795 shares at prices ranging from $146.0277 to $149.575 per share. Following these transactions, Fesko holds 157,289 shares directly. The stock, currently trading at $150.87, has delivered an impressive 62.4% return over the past year, though InvestingPro analysis suggests the shares are trading above their Fair Value.
The sale was conducted to meet tax withholding obligations related to the vesting of restricted stock units (RSUs), as per a prearranged trading plan compliant with Rule 10b5-1(c) under the Exchange Act. The company maintains a strong financial position with a current ratio of 4.0 and operates with moderate debt levels. For deeper insights into Natera’s financial health and growth prospects, including 11 additional exclusive ProTips, check out the comprehensive research report available on InvestingPro.
In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, which exceeded Wall Street expectations with a narrower-than-anticipated loss per share and higher revenue. The company posted an earnings per share of -$0.41, better than the forecasted -$0.49, and revenue reached $476 million, surpassing the predicted $409.89 million. Additionally, Natera’s revenue grew 53% year-over-year, with gross margins improving significantly to 63%. Canaccord Genuity responded by raising its price target for Natera to $195 from $180, maintaining a Buy rating due to the strong fourth-quarter results and optimistic 2025 guidance. Similarly, TD Cowen reaffirmed its Buy rating with a $195 price target, highlighting Natera’s 2025 guidance, which exceeds consensus estimates by approximately 5%. In other developments, Natera has initiated the HEROES clinical trial to explore treatment de-escalation in metastatic HER2+ breast cancer patients, potentially impacting future treatment approaches. The trial will involve approximately 170 participants across 35 sites in France, focusing on the feasibility of ctDNA-guided treatment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.